Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


340B Providers Offer Varying Approaches To Tracking, Using Discounts At Hearing

Executive Summary

House Energy and Commerce Committee Chair Greg Walden, R-Ore., expresses frustration at lack of reliable data on the way providers account for 340B drug discounts at Oct. 11 hearing.


Related Content

340B Provider Reforms Gaining Momentum In Congress
Medicare Lowers Payments For 340B Drugs: Promising Sign For Further Reform?
340B Reforms: Oversight Hearing Suggests Slow, Piecemeal Approach





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts